San Diego-based Dexcom, which expects to launch G7 soon ahead of what President and CEO Kevin Sayer said will be a year full of activity, conducted the study in adults with either type 1 or type 2 diabetes (on intensive insulin therapy or not).
Get the full story at our sister site, Drug Delivery Business News.